nach oben

Social Psychiatry and Psychiatric Epidemiology

Erschienen in:

29.04.2019 | Original Paper

Concurrent use of benzodiazepines, antidepressants, and opioid analgesics with zolpidem and risk for suicide: a case–control and case–crossover study

verfasst von: Hi Gin Sung, Junquing Li, Jin Hyun Nam, Dae Yeon Won, BongKyoo Choi, Ju-Young Shin

Erschienen in: Social Psychiatry and Psychiatric Epidemiology | Ausgabe 12/2019

Einloggen, um Zugang zu erhalten

Abstract

Purpose

To evaluate whether the concurrent use of benzodiazepines, antidepressants, and opioid analgesics with zolpidem increases the risk of suicide or triggers suicide compared with the use of zolpidem alone.

Methods

We conducted a case–control and case–crossover study using the Korean National Health Insurance Service-National Sample Cohort database. Cases were older than 20 years with a suicide record (International Codes of Disease 10th Revision codes: X-60-X84 and Y87.0 intentional self-harm) between January 1, 2004, and December 31, 2013. For case–control design, ten controls were matched to each case by age, sex, index year, region, income, and health insurance type. For case–crossover analysis, we set hazard period to 60 days and assigned five corresponding sets of control periods of equal length. Exposure was assessed during 60 days before suicide for combinations of benzodiazepines, antidepressants, opioid analgesics with zolpidem against zolpidem alone. We conducted a conditional logistic regression to estimate odds ratios (ORs) and their 95% confidence intervals (CIs).

Results

In the case–control study, the risk of suicide was 2.80-fold higher in cases taking benzodiazepines and antidepressants with zolpidem than in those taking zolpidem alone (adjusted OR [aOR], 2.80; 95% CI, 1.38–5.70). However, in the case–crossover study, suicide risk showed no significant difference (crude OR [cOR], 0.92; 95% CI, 0.55–1.52) and was underpowered.

Conclusions

The results of the traditional case–control study confirmed that the concurrent use of benzodiazepines and antidepressants with zolpidem was associated with an increased risk of suicide compared with the use of zolpidem alone. However, there was no significant difference in the magnitude of risk in the within-person comparison design.

Nur mit Berechtigung zugänglich

de Haas SL, Schoemaker RC, van Gerven JM, Hoever P, Cohen AF, Dingemanse J (2010) Pharmacokinetics, pharmacodynamics and the pharmacokinetic/pharmacodynamic relationship of zolpidem in healthy subjects. J Psychopharmacol 24(11):1619–1629. https://doi.org/10.1177/0269881109106898(Oxford, England) CrossRefPubMed

Baselt RC (2008) Disposition of toxic drugs and chemicals in man, 8th edn. Biomedical Publishers, Foster City, CA

Whyte J, Myers R (2009) Incidence of clinically significant responses to zolpidem among patients with disorders of consciousness: a preliminary placebo controlled trial. Am J Phys Med Rehabil 88(5):410–418. https://doi.org/10.1097/PHM.0b013e3181a0e3a0 CrossRefPubMed

Darcourt G, Pringuey D, Salliere D, Lavoisy J (1999) The safety and tolerability of zolpidem—an update. J Psychopharmacol 13(1):81–93. https://doi.org/10.1177/026988119901300109(Oxford, England) CrossRefPubMed

Ben-Hamou M, Marshall NS, Grunstein RR, Saini B, Fois RA (2011) Spontaneous adverse event reports associated with zolpidem in Australia 2001–2008. J Sleep Res 20(4):559–568. https://doi.org/10.1111/j.1365-2869.2011.00919.x CrossRefPubMed

Bush DM (2013) Emergency department visits attributed to overmedication that involved the insomnia medication zolpidem. In: The CBHSQ report. Substance abuse and mental health services administration (US), Rockville (MD),

McCall WV, Benca RM, Rosenquist PB, Riley MA, McCloud L, Newman JC, Case D, Rumble M, Krystal AD (2017) Hypnotic medications and suicide: risk, mechanisms, mitigation, and the FDA. Am J Psychiatry 174(1):18–25. https://doi.org/10.1176/appi.ajp.2016.16030336 CrossRefPubMed

Wong CK, Marshall NS, Grunstein RR, Ho SS, Fois RA, Hibbs DE, Hanrahan JR, Saini B (2017) Spontaneous adverse event reports associated with zolpidem in the United States 2003–2012. J Clin Sleep Med 13(2):223–234. https://doi.org/10.5664/jcsm.6452 CrossRefPubMedPubMedCentral

Tj M (2015) ISMP quarter watch: monitoring FDA MedWatch reports. ISMP, Philadelphia

10.

Mary Ross Southwork-Division of drug risk evaluation (2006) ODS Postmarketing safety review drug(s) zaleplon (20-859)-eszopiclone (21-476)-zolpidem (19-908) Event-suicidal ideation and attempts-completed suicides. Center for Drug Evaluation and Research of the Food and Drug Administration; D050402 D050403 D050404;8-31-2006, Rockville, MD

11.

Lee D, Delcher C, Maldonado-Molina MM, Thogmartin JR, Goldberger BA (2016) Manners of death in drug-related fatalities in Florida. J Forensic Sci 61(3):735–742. https://doi.org/10.1111/1556-4029.12999 CrossRefPubMed

12.

Dodds TJ (2017) Prescribed benzodiazepines and suicide risk: a review of the literature. Prim Care Companion CNS Disord. https://doi.org/10.4088/pcc.16r02037 CrossRefPubMed

13.

Bielefeldt AO, Danborg PB, Gotzsche PC (2016) Precursors to suicidality and violence on antidepressants: systematic review of trials in adult healthy volunteers. J R Soc Med 109(10):381–392. https://doi.org/10.1177/0141076816666805 CrossRefPubMedPubMedCentral

14.

Ilgen MA, Bohnert AS, Ganoczy D, Bair MJ, McCarthy JF, Blow FC (2016) Opioid dose and risk of suicide. Pain 157(5):1079–1084. https://doi.org/10.1097/j.pain.0000000000000484 CrossRefPubMedPubMedCentral

15.

Bertisch SM, Herzig SJ, Winkelman JW, Buettner C (2014) National use of prescription medications for insomnia: NHANES 1999–2010. Sleep 37(2):343–349. https://doi.org/10.5665/sleep.3410 CrossRefPubMedPubMedCentral

16.

Sun EC, Dixit A, Humphreys K, Darnall BD, Baker LC, Mackey S (2017) Association between concurrent use of prescription opioids and benzodiazepines and overdose: retrospective analysis. BMJ 356:j760. https://doi.org/10.1136/bmj.j760(Clinical research ed) CrossRefPubMedPubMedCentral

17.

Turner BJ, Liang Y (2015) Drug overdose in a retrospective cohort with non-cancer pain treated with opioids, antidepressants, and/or sedative-hypnotics: interactions with mental health disorders. J Gen Intern Med 30(8):1081–1096. https://doi.org/10.1007/s11606-015-3199-4 CrossRefPubMedPubMedCentral

18.

Tsuno N, Besset A, Ritchie K (2005) Sleep and depression. J Clin Psychiatry 66(10):1254–1269CrossRefPubMed

19.

Thase ME (2006) Depression and sleep: pathophysiology and treatment. Dialogues Clin Neurosci 8(2):217–226PubMedPubMedCentral

20.

Amihaesei IC, Mungiu OC (2012) Main neuroendocrine features and therapy in primary sleep troubles. Rev Med Chir Soc Med Nat Iasi 116(3):862–866PubMed

21.

Niedrig DF, Hoppe L, Machler S, Russmann H, Russmann S (2016) Benzodiazepine use during hospitalization: automated identification of potential medication errors and systematic assessment of preventable adverse events. PLoS One 11(10):e0163224. https://doi.org/10.1371/journal.pone.0163224 CrossRefPubMedPubMedCentral

22.

Zin CS, Ismail F (2017) Co-prescription of opioids with benzodiazepine and other co-medications among opioid users: differential in opioid doses. J Pain Res 10:249–257. https://doi.org/10.2147/jpr.s122853 CrossRefPubMedPubMedCentral

23.

Geoffroy PA, Hoertel N, Etain B, Bellivier F, Delorme R, Limosin F, Peyre H (2018) Insomnia and hypersomnia in major depressive episode: prevalence, sociodemographic characteristics and psychiatric comorbidity in a population-based study. J Affect Disord 226:132–141. https://doi.org/10.1016/j.jad.2017.09.032 CrossRefPubMed

24.

Darke S, Deady M, Duflou J (2012) Toxicology and characteristics of deaths involving zolpidem in New South Wales, Australia 2001–2010. J Forensic Sci 57(5):1259–1262. https://doi.org/10.1111/j.1556-4029.2012.02117.x CrossRefPubMed

25.

Delaveris GJ, Teige B, Rogde S (2014) Non-natural manners of death among users of illicit drugs: substance findings. Forensic Sci Int 238:16–21. https://doi.org/10.1016/j.forsciint.2014.02.009 CrossRefPubMed

26.

Poulter MO, Du L, Weaver IC, Palkovits M, Faludi G, Merali Z, Szyf M, Anisman H (2008) GABAA receptor promoter hypermethylation in suicide brain: implications for the involvement of epigenetic processes. Biol Psychiatry 64(8):645–652. https://doi.org/10.1016/j.biopsych.2008.05.028 CrossRefPubMed

27.

Klempan TA, Sequeira A, Canetti L, Lalovic A, Ernst C, Ffrench-Mullen J, Turecki G (2009) Altered expression of genes involved in ATP biosynthesis and GABAergic neurotransmission in the ventral prefrontal cortex of suicides with and without major depression. Mol Psychiatry 14(2):175–189. https://doi.org/10.1038/sj.mp.4002110 CrossRefPubMed

28.

Sequeira A, Mamdani F, Ernst C, Vawter MP, Bunney WE, Lebel V, Rehal S, Klempan T, Gratton A, Benkelfat C, Rouleau GA, Mechawar N, Turecki G (2009) Global brain gene expression analysis links glutamatergic and GABAergic alterations to suicide and major depression. PLoS One 4(8):e6585. https://doi.org/10.1371/journal.pone.0006585 CrossRefPubMedPubMedCentral

29.

Choudary PV, Molnar M, Evans SJ, Tomita H, Li JZ, Vawter MP, Myers RM, Bunney WE Jr, Akil H, Watson SJ, Jones EG (2005) Altered cortical glutamatergic and GABAergic signal transmission with glial involvement in depression. Proc Natl Acad Sci USA 102(43):15653–15658. https://doi.org/10.1073/pnas.0507901102 CrossRefPubMedPubMedCentral

30.

Merali Z, Du L, Hrdina P, Palkovits M, Faludi G, Poulter MO, Anisman H (2004) Dysregulation in the suicide brain: mRNA expression of corticotropin-releasing hormone receptors and GABA(A) receptor subunits in frontal cortical brain region. J Neurosci 24(6):1478–1485. https://doi.org/10.1523/jneurosci.4734-03.2004 CrossRefPubMedPubMedCentral

31.

Asberg M, Thoren P, Traskman L, Bertilsson L, Ringberger V (1976) “Serotonin depression”—a biochemical subgroup within the affective disorders? Science 191(4226):478–480 (New York, NY) CrossRefPubMed

32.

Arango V, Underwood MD, Mann JJ (2002) Serotonin brain circuits involved in major depression and suicide. Prog Brain Res 136:443–453CrossRefPubMed

33.

Saltiel PF, Silvershein DI (2015) Major depressive disorder: mechanism-based prescribing for personalized medicine. Neuropsychiatr Dis Treat 11:875–888. https://doi.org/10.2147/ndt.s73261 CrossRefPubMedPubMedCentral

34.

Brower KJ, McCammon RJ, Wojnar M, Ilgen MA, Wojnar J, Valenstein M (2011) Prescription sleeping pills, insomnia, and suicidality in the national comorbidity survey replication. J Clin Psychiatry 72(4):515–521. https://doi.org/10.4088/JCP.09m05484gry CrossRefPubMed

35.

Sun Y, Lin CC, Lu CJ, Hsu CY, Kao CH (2016) Association between zolpidem and suicide: a nationwide population-based case–control study. Mayo Clin Proc 91(3):308–315. https://doi.org/10.1016/j.mayocp.2015.10.022 CrossRefPubMed

36.

Choi B, Sung HG, Nam JH, Shin JY (2019) Zolpidem use and suicide death in South Korea: a population-based case–control study. Suicide Life Threat Behav. https://doi.org/10.1111/sltb.12548 CrossRefPubMed

37.

Won T, Kang B, Im T, Choi H (2007) The study of accuracy of death statistics (original articles: the study of accuracy of death statistics). J Korean Soc Emerg Med 18(3):256–262

38.

Maclure M (1991) The case–crossover design: a method for studying transient effects on the risk of acute events. Am J Epidemiol 133(2):144–153CrossRefPubMed

39.

Olesen JB, Hansen PR, Erdal J, Abildstrom SZ, Weeke P, Fosbol EL, Poulsen HE, Gislason GH (2010) Antiepileptic drugs and risk of suicide: a nationwide study. Pharmacoepidemiol Drug Saf 19(5):518–524. https://doi.org/10.1002/pds.1932 CrossRefPubMed

40.

Bjorkenstam C, Moller J, Ringback G, Salmi P, Hallqvist J, Ljung R (2013) An association between initiation of selective serotonin reuptake inhibitors and suicide—a nationwide register-based case–crossover study. PLoS One 8(9):e73973. https://doi.org/10.1371/journal.pone.0073973 CrossRefPubMedPubMedCentral

41.

Bagge CL, Borges G (2017) Acute substance use as a warning sign for suicide attempts: a case–crossover examination of the 48 h prior to a recent suicide attempt. J Clin Psychiatry 78(6):691–696. https://doi.org/10.4088/JCP.15m10541 CrossRefPubMed

42.

Charlson ME, Pompei P, Ales KL, MacKenzie CR (1987) A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis 40(5):373–383CrossRefPubMed

43.

Maclure M, Mittleman MA (2000) Should we use a case–crossover design? Annu Rev Public Health 21:193–221. https://doi.org/10.1146/annurev.publhealth.21.1.193 CrossRefPubMed

44.

Maclure M, Fireman B, Nelson JC, Hua W, Shoaibi A, Paredes A, Madigan D (2012) When should case-only designs be used for safety monitoring of medical products? Pharmacoepidemiol Drug Saf 21(Suppl 1):50–61. https://doi.org/10.1002/pds.2330 CrossRefPubMed

45.

Neutel CI, Patten SB (1997) Risk of suicide attempts after benzodiazepine and/or antidepressant use. Ann Epidemiol 7(8):568–574CrossRefPubMed

46.

Fontanella CA, Campo JV, Phillips GS, Hiance-Steelesmith DL, Sweeney HA, Tam K, Lehrer D, Klein R, Hurst M (2016) Benzodiazepine use and risk of mortality among patients with schizophrenia: a retrospective longitudinal study. J Clin Psychiatry 77(5):661–667. https://doi.org/10.4088/JCP.15m10271 CrossRefPubMed

47.

Bouchette D, Quick J (2019) Zolpidem. In: StatPearls. StatPearls Publishing, StatPears Publishing LLC.,Treasure Island, FL

48.

Lee R, Petty F, Coccaro EF (2009) Cerebrospinal fluid GABA concentration: relationship with impulsivity and history of suicidal behavior, but not aggression, in human subjects. J Psychiatr Res 43(4):353–359. https://doi.org/10.1016/j.jpsychires.2008.04.004 CrossRefPubMed

49.

Turecki G, Brent DA (2016) Suicide and suicidal behaviour. Lancet 387(10024):1227–1239. https://doi.org/10.1016/s0140-6736(15)00234-2(London, England) CrossRefPubMed

50.

Hooten WM (2016) Chronic pain and mental health disorders: shared neural mechanisms, epidemiology, and treatment. Mayo Clin Proc 91(7):955–970. https://doi.org/10.1016/j.mayocp.2016.04.029 CrossRefPubMed

51.

Hooley JM, Franklin JC, Nock MK (2014) Chronic pain and suicide: understanding the association. Curr Pain Headache Rep 18(8):435. https://doi.org/10.1007/s11916-014-0435-2 CrossRefPubMed

Titel: Concurrent use of benzodiazepines, antidepressants, and opioid analgesics with zolpidem and risk for suicide: a case–control and case–crossover study
verfasst von: Hi Gin Sung
Junquing Li
Jin Hyun Nam
Dae Yeon Won
BongKyoo Choi
Ju-Young Shin
Publikationsdatum: 29.04.2019
Verlag: Springer Berlin Heidelberg
Erschienen in: Social Psychiatry and Psychiatric Epidemiology / Ausgabe 12/2019
Print ISSN: 0933-7954
Elektronische ISSN: 1433-9285
DOI: https://doi.org/10.1007/s00127-019-01713-x

Neu im Fachgebiet Psychiatrie

23.04.2024 | Depression antepartal oder postpartal | Nachrichten

Update Psychiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Concurrent use of benzodiazepines, antidepressants, and opioid analgesics with zolpidem and risk for suicide: a case–control and case–crossover study

Abstract

Purpose

Methods

Results

Conclusions

Neu im Fachgebiet Psychiatrie

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Psychiatrie

Live-Webinar: Aktuelle Leitlinien bei Herz-Kreislauf-Erkrankungen

Springer Medizin

Abstract

Purpose

Methods

Results

Conclusions

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Ausgabe 12/2019

Barriers and predictors of medication use for childhood ADHD: findings from a UK population-representative cohort

Factors associated with discontinuation of antidepressant treatment after a single prescription among patients aged 55 or over: evidence from English primary care

Spatiotemporal clustering of suicides in the US from 1999 to 2016: a spatial epidemiological approach

The role of neuroticism in self-harm and suicidal ideation: results from two UK population-based cohorts

Trends in psychiatric disorders prevalence and prescription patterns of children in Alberta, Canada

Suicide risk around the world: a meta-analysis of longitudinal studies

Neu im Fachgebiet Psychiatrie

Weniger postpartale Depressionen nach Esketamin-Einmalgabe

„Psychotherapie ist auch bei sehr alten Menschen hochwirksam!“

Auf diese Krankheiten bei Geflüchteten sollten Sie vorbereitet sein

Hustenstiller lindert Agitation bei Alzheimer

Update Psychiatrie